Japan Daily Briefing

Toyo Keizai Online highlighted Hokko Chemical (北興化学) as a mid-cap pick with a compelling semiconductor supply-chain angle: the company makes raw materials for photoresist — the chemical layer essential in advanced lithography for TSMC, Samsung, and Tokyo Electron's customers. Demand is surging as EUV and DUV lithography cycles accelerate, yet Hokko trades at a discount PER even as its dividend has grown 5x over the past decade. In a session where the TOPIX is being punished broadly, this kind of deep-supply-chain, domestic-demand story with pricing power is exactly what value-rotation buyers should be accumulating — it's the opposite of SoftBank's Vision Fund leverage.

Toyo Keizai Online published a data-driven rebuttal to Japan's perennial fiscal-crisis narrative — the one where each Japanese citizen 'owes ¥11 million in national debt.' The piece walks through the government's consolidated balance sheet (including the Bank of Japan), which dramatically changes the net debt picture vs gross debt. For BoJ watchers, this matters because the JGB yield curve (YCC policy formally ended but BoJ is still the dominant buyer) shapes USD/JPY basis and the carry-trade infrastructure. A Japan fiscal credibility narrative that holds means BoJ normalization proceeds at its own pace — if the narrative breaks, JGB volatility becomes a tail risk for every JPY-funded carry.

Toyo Keizai notes that while Kioxia Holdings and SoftBank Group drove the large-cap headline numbers in recent sessions, mid-cap screeners are surfacing compelling valuation opportunities across sectors including specialty chemicals and capital goods — names that missed the AI-hype rally but benefit from Japan's corporate governance reform push (PBR<1 buyback pressure, TSE Prime Market requirements). Today's -4% session in the Japan ETF is precisely the kind of reset that mid-cap value buyers have been waiting for. The sogo shosha Buffett thesis (Sumitomo, Mitsui, Mitsubishi) also looks more interesting on dips like this — their commodity exposure and balance sheet discipline is counter-cyclical to SoftBank-style tech leverage.